ATRI vs. CSII, KIDS, ATRC, QDEL, ICUI, STAA, ANIK, OSUR, CERS, and UTMD
Should you be buying Atrion stock or one of its competitors? The main competitors of Atrion include Cardiovascular Systems (CSII), OrthoPediatrics (KIDS), AtriCure (ATRC), QuidelOrtho (QDEL), ICU Medical (ICUI), STAAR Surgical (STAA), Anika Therapeutics (ANIK), OraSure Technologies (OSUR), Cerus (CERS), and Utah Medical Products (UTMD). These companies are all part of the "medical" sector.
Atrion (NASDAQ:ATRI) and Cardiovascular Systems (NASDAQ:CSII) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, community ranking, dividends, valuation, earnings and profitability.
66.2% of Atrion shares are held by institutional investors. Comparatively, 86.6% of Cardiovascular Systems shares are held by institutional investors. 22.8% of Atrion shares are held by insiders. Comparatively, 3.8% of Cardiovascular Systems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Cardiovascular Systems received 289 more outperform votes than Atrion when rated by MarketBeat users. Likewise, 61.93% of users gave Cardiovascular Systems an outperform vote while only 54.66% of users gave Atrion an outperform vote.
In the previous week, Atrion had 4 more articles in the media than Cardiovascular Systems. MarketBeat recorded 4 mentions for Atrion and 0 mentions for Cardiovascular Systems. Atrion's average media sentiment score of 0.92 beat Cardiovascular Systems' score of -0.11 indicating that Atrion is being referred to more favorably in the media.
Atrion has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Cardiovascular Systems has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.
Atrion has a net margin of 10.60% compared to Cardiovascular Systems' net margin of -15.79%. Atrion's return on equity of 7.75% beat Cardiovascular Systems' return on equity.
Atrion has higher earnings, but lower revenue than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.
Summary
Atrion beats Cardiovascular Systems on 10 of the 15 factors compared between the two stocks.
Get Atrion News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
